GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » 6-1 Month Momentum %

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) 6-1 Month Momentum % : 200.00% (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-06), Checkmate Pharmaceuticals's 6-1 Month Momentum % is 200.00%.

The industry rank for Checkmate Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

CMPI's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -4.76 vs CMPI: 200.00

Competitive Comparison of Checkmate Pharmaceuticals's 6-1 Month Momentum %

For the Biotechnology subindustry, Checkmate Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkmate Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's 6-1 Month Momentum % falls into.



Checkmate Pharmaceuticals  (NAS:CMPI) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Checkmate Pharmaceuticals  (NAS:CMPI) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Checkmate Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash director, officer: Chief Executive Officer C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg director, officer: Chief Scientific Officer C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski officer: Chief Financial Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger director, officer: President and CEO C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono director C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff director C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan officer: Chief Operating Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary officer: Chief Business Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines